VTRS - Viatris receives offer to divest all of it's over the counter business
2023-10-02 06:35:13 ET
More on Viatris
- Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss
- Why 5%-Yielding Viatris Hasn't Doubled Yet
- Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market
- Novo Nordisk underperforms as Viatris fights Wegovy patents
- Viatris and Ocuphire Pharma announce FDA approval for eye drop formulation RYZUMVl
For further details see:
Viatris receives offer to divest all of it's over the counter business